Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial - Patel, Anup D.; Mazurkiewicz‐Bełdzińska, Maria; Chin, Richard F.; Gil‐Nagel, Antonio; Gunning, Boudewijn; Halford, Jonathan J.; Mitchell, Wendy; Scott Perry, Michael; Thiele, Elizabeth A.; Weinstock, Arie; Dunayevich, Eduardo; Checketts, Daniel; et al. (Epilepsia (Copenhagen), 2021)
Keywords: Adverse events; Anticonvulsants - adverse effects; Cannabidiol; Cannabidiol - therapeutic use; cannabinoid; Cannabinoids; childhood onset epilepsy; Clinical trials; Convulsions & seizures; Diarrhea; drop seizures; Encephalopathy; Epilepsies, Myoclonic - drug therapy; Epilepsy; epileptic encephalopathy; Fever; Humans; Lennox Gastaut Syndrome - drug therapy; Patients; Safety; Seizures; Seizures - drug therapy; Transaminase; treatment resistant; Valproic acid; childhood onset epilepsy; treatment resistant; drop seizures; cannabinoid; epileptic encephalopathy